FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
OIPE SCIE	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	01-034	09/760,119
FEB 1 7. 2004	(Use several sheets if necessary)	Applicant:	
MADEMATTI		Sarah S. Bacus	
MADEBIT	•	Filing Date:	Group:
		01/12/2001	1642

# **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

# **FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Trans	slation
					Yes	No

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAC	KAC 1.		Bacus et al., "Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells," Oncogene 12(12):2535-47, 1996.
		2.	Chang et al., "p21 <sup>Waf1/Cip1/Sdi1</sup> -induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells," Oncogene 19:2165-2170, 2000.
		3.	Kopp et al., "Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen," Cancer Research 55(20):4512-4515, 1995.
4. Lei et al., "The expression of suppressor gene p16, p21 and p53 in n Hou Ke Za Zhi 13(9):406-8, 1999.		4.	Lei et al., "The expression of suppressor gene p16, p21 and p53 in nasopharyngeal carcinoma," Lin Chuang Er Bi Yan Hou Ke Za Zhi 13(9):406-8, 1999.
		5.	Meyn et al., "Apoptosis in murine tumors treated with chemotherapy agents," Anti-Cancer Drugs 6:443-450, 1995.
		6.	Shibata et al., "Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21," Cancer Gene Therapy 8:23-35, 2001.
\		7.	Timmermann et al., "Re-expression of endogenous p16 <sup>ink4a</sup> in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state," Oncogene 17(26):3445-53, 1998.

EXAMINER /Karen A Canella	Dh D /	DATE CONCIDENCE	
EXAMINER /Karen A. Canella	, Pn.D./	DATE CONSIDERED	07/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

IDS - 04/05/2005

FORM PTO-1449 (Rev. 2-32)				
LET O S TRUBBLE OF THE PARTY OF THE PARTY OF THE PROPERTY OF THE PARTY	いるまと			

# U.S. Department of Commerce Patent and Trademark Office

merce Atty. Docket No. Office

Serial No.

01-034

09/760,119

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

Applicant:
Sarah S. Bacus

Filing Date:

Group:

01/12/2001

1642

### **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

#### **FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAC	1.	Dannecker et al.; Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D; Ann. Onc., Apr 1996; 7: 391 - 395.
KAC	2.	Gillett et al.; Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma; J Pathol, Jan 1999; 187(2): 200-6.
KAC	3.	Smith et al.; Primary chemotherapy in breast cancer; Biomed Pharmacother, Jan 1998; 52(3): 116-21.
KAC	4.	Srivastava et al.; Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells; Anticancer Res, Nov 1998; 18(6A): 4003-10.
KAC	5.	Vollmer et al.; Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors; Cancer Res., Sep 1992; 52: 4642 - 4648.

EXAMINER	/Karen A.	Canella,	Ph.D./	DATE CONSIDERED	07/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.